Baird analyst Eric Coldwell raised the firm’s price target on Medpace to $312 from $302 and keeps an Outperform rating on the shares. The firm expects a strong 2023 finish, with top, middle- and bottom-line results at upper end of guidance.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on MEDP:
